Amarogentin Inhibits Cell Viability and Promotes Apoptosis in Breast Cancer MDA-MB-231 Cells via Increasing Oxidative Stress and Inhibiting PI3K/AKT/mTOR Pathway
Pharmacognosy Magazine · 2026-12 · 22 (4) · 1473-1480
DOI: 10.1177/09731296261444835 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacognosy Magazine, online erschienen am 12.05.2026. Verfasst von Minxiang Wei und 5 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Breast cancer is the most common cancer type in women globally, constituting a substantial portion of all documented female malignancies. It is the second major cause of cancer-associated mortality in women, with over one million new diagnoses each year.
Objectives
The present work evaluated the anti-cancer activity of amarogentin by assessing its growth-inhibition and apoptosis-triggering capabilities against breast cancer cells. Materials and Methods The cytotoxic effects of amarogentin at various dosages on MDA-MB-231 cells were evaluated using the MTT test. The incidences of apoptosis in amarogentin-induced cells were evaluated using a dual staining technique. The concentrations of oxidative stress markers and PI3K/AKT/mTOR proteins were evaluated in amarogentin-treated cells utilizing kits.
Results
The current findings demonstrate that the MDA-MB-231 cell viability was diminished after treatment with diverse dosages of amarogentin. The amarogentin treatment significantly enhanced apoptotic incidences in MDA-MB-231 cells, as seen by the dual staining assay results. The amarogentin treatment elevated thiobarbituric acid reactive substances level and subsequently diminished antioxidants in the MDA-MB-231 cells. Furthermore, amarogentin suppressed PI3K/AKT/mTOR proteins in the breast cancer cells.
Conclusion
The current findings indicate that amarogentin treatment significantly reduces cell viability and promotes oxidative stress-dependent apoptosis in breast cancer cells. Therefore, it has the potential to serve as an anti-cancer candidate for breast cancer treatment.
Zitieren
APA
Wei, M., Gu, Y., Han, C., Liu, Y., Yan, L., & Gao, R. (2026). Amarogentin Inhibits Cell Viability and Promotes Apoptosis in Breast Cancer MDA-MB-231 Cells via Increasing Oxidative Stress and Inhibiting PI3K/AKT/mTOR Pathway. Pharmacognosy Magazine, 22(4), 1473-1480. https://doi.org/10.1177/09731296261444835
Vancouver
Wei M, Gu Y, Han C, Liu Y, Yan L, Gao R. Amarogentin Inhibits Cell Viability and Promotes Apoptosis in Breast Cancer MDA-MB-231 Cells via Increasing Oxidative Stress and Inhibiting PI3K/AKT/mTOR Pathway. Pharmacognosy Magazine. 2026;22(4):1473-1480. doi:10.1177/09731296261444835
BibTeX
@article{Wei2026,
author = {Wei, Minxiang and Gu, Yujie and Han, Cuiyu and Liu, Yuanyuan and Yan, Lu and Gao, Rui},
title = {Amarogentin Inhibits Cell Viability and Promotes Apoptosis in Breast Cancer MDA-MB-231 Cells via Increasing Oxidative Stress and Inhibiting PI3K/AKT/mTOR Pathway},
journal = {Pharmacognosy Magazine},
year = {2026},
volume = {22},
number = {4},
pages = {1473--1480},
doi = {10.1177/09731296261444835}
}
EUVIMED